OverviewDr. Charles C. Wykoff is a board-certified Medical and Surgical Retina Specialist and ophthalmologist with Retina Consultants of Texas (RCTX). Leading a top international research facility for vitreoretinal diseases, Dr. Wykoff serves as Director of Research at RCTX and the Greater Houston Retina Research Foundation (GHRRF), and Chairman of the Research and Clinical Trials Subcommittee, Retina Consultants of America. In addition, he serves as the elected Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital. Dr. Wykoff has been awarded the American Academy of Ophthalmology Secretariat and Achievement Awards as well as the American Society of Retina Specialists Senior Honor and Young Investigator Awards.
“I know the quality of my vision would not be as excellent as it is now if it were not for Dr. Wykoff’s excellent care. I feel so blessed to have him as my doctor. I have always been treated with the utmost respect at his office and feel that I always have excellent care with every visit.”D.S.
Meet Charles C. Wykoff, M.D., PhD
Skills and SpecialtiesDr. Wykoff is passionate about translational research and clinical trial design, and serves as principal investigator for numerous national clinical trials. publishing over 160 peer-reviewed scientific articles and frequently speaks at national and international academic meetings. His research interests pertain to angiogenesis and retinal vascular diseases including age-related macular degeneration, diabetic retinopathy, and venous occlusive diseases, as well as vitreoretinal surgical topics such as retinal tears and retinal detachments, as well as macular surgery for macular holes and macular puckers. He is highly trained and skilled to perform a variety of surgical procedures, and also works with patients to hold off surgery as long as possible with conservative, nonsurgical treatment when possible.
He serves on multiple scientific advisory boards and global clinical-trial steering committees for endeavors spanning the innovative process from early to late stage development. He is foundationally involved with entrepreneurial activities focused on bringing the value of clinical trials to new centers across the globe, on improving the efficiency of clinical trial design, and on optimizing the quality of data collected from prospective studies. His guiding philosophy is to build and strengthen innovative, ethical teams focused on developing new approaches to improving outcomes for blinding diseases.